The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InHims & Hers Health has raised its 2026 revenue guidance to $3 billion, a figure that exceeds current market consensus. The company is maintaining a long-term target of achieving at least 20% EBITDA margins by 2030. However, according to reports, the firm is navigating near-term margin pressures linked to branded GLP-1 medications and its ongoing international scaling efforts.
This upward revision comes as the telehealth sector faces shifting dynamics; competitor Ro recently expanded its weight management offerings, while Teladoc Health reported wider losses in its latest quarterly filing per search data. Hims & Hers appears to be moving past the GLP-1 transition phase, and notably, the updated guidance does not yet factor in the potential impact of the Eucalyptus acquisition, according to analyst reports.
Investors will be watching for the company's ability to maintain growth while managing costs associated with international expansion. On the macro front, market participants are looking ahead to the US Inflation Rate (CPI) data scheduled for May 12, 2026, which could impact valuation multiples for high-growth telehealth stocks. Execution on the 2030 margin targets remains a primary catalyst for long-term sentiment.